A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
NCT03505125 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63
Last updated 2020-01-14
Summary
The 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with PKU.
Conditions
- Phenylketonuria (PKU)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director, MD · BioMarin Pharmaceutical
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-31
- Primary Completion
- 2019-07-31
- Completion
- 2019-07-31
Countries
- United States
- Canada
- France
- Germany
- Italy
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
NCT07220265 ·Status: RECRUITING ·Phase: NA
-
Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
NCT05356377 ·Status: COMPLETED
-
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
NCT01819727 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.
NCT05827536 ·Status: TERMINATED ·Phase: NA
-
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
NCT00225615 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
NCT01889862 ·Status: COMPLETED ·Phase: PHASE3
-
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
NCT01924026 ·Status: COMPLETED
-
Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors
NCT00728676 ·Status: COMPLETED
-
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
NCT04404530 ·Status: RECRUITING
-
GMP Drink for PKU Study
NCT02915510 ·Status: COMPLETED ·Phase: NA
-
Study of a National Cohort of Adult Patients With Phenylketonuria
NCT01619722 ·Status: COMPLETED
-
Antioxidant Signature in Adult Patients With Phenylketonuria
NCT02212288 ·Status: COMPLETED
-
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678 ·Status: RECRUITING
-
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
NCT01560286 ·Status: COMPLETED ·Phase: PHASE2
-
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
NCT05579548 ·Status: RECRUITING
-
Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
NCT01212744 ·Status: COMPLETED ·Phase: PHASE2
-
AAV Gene Therapy Study for Subjects with PKU
NCT04480567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
NCT00838435 ·Status: COMPLETED ·Phase: PHASE3
-
Testing of Four Home Phenylalanine Monitoring Prototype Devices
NCT02445521 ·Status: COMPLETED
-
Natural History Clinical Study in Adult PKU
NCT04768348 ·Status: TERMINATED
-
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
NCT00778206 ·Status: COMPLETED
-
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
NCT01965912 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of PKU Explore
NCT03168399 ·Status: COMPLETED ·Phase: NA
-
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Synergy on Nutrient Intake and Acceptability in Phenylketonuria (PKU)
NCT03777826 ·Status: COMPLETED ·Phase: NA